Product Description
Maribavir is a benzimidazole riboside with activity against cytomegalovirus (CMV). (Sourced from: https://www.nejm.org/doi/full/10.1056/NEJMoa1714656)
Mechanisms of Action: pUL97 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Brazil, China, France, Germany, Israel, Japan, Spain, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Cytomegalovirus Infections|Hematopoietic Stem Cell Transplant|Transplantation Unspecified
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TAK-620-2004 | P3 |
Temporary halt |
Hematopoietic Stem Cell Transplant|Transplantation Unspecified |
2027-03-31 |
35% |
| jRCT2021210056 | P3 |
Completed |
Hematopoietic Stem Cell Transplant|Transplantation Unspecified |
2023-06-27 |
8% |
| jRCT2031230753 | P3 |
Recruiting |
Transplantation Unspecified|Hematopoietic Stem Cell Transplant |
2026-11-22 |
35% |
| TAK-620-3001 | P3 |
Completed |
Cytomegalovirus Infections |
2023-06-27 |
8% |
| TAK-620-2004 | P3 |
Active, not recruiting |
Cytomegalovirus Infections |
2027-01-18 |
35% |
| TAK-620-1024 | P1 |
Completed |
Healthy Volunteers |
2023-08-25 |
69% |
| TAK-620-3002 | P3 |
Recruiting |
Cytomegalovirus Infections |
2026-12-31 |
44% |